Recursion Pharmaceuticals (RXRX) Share-based Compensation (2020 - 2026)

Recursion Pharmaceuticals has reported Share-based Compensation for 7 years, with the latest figure at $22.2 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 38.39% year-over-year to $22.2 million; the trailing twelve-month figure through Mar 2026 stood at $97.4 million (down 4.17% YoY), and the FY2025 full-year result was $111.2 million, up 36.16% from the prior year.
• Share-based Compensation for Q1 2026 stood at $22.2 million, down from $23.8 million in the prior quarter.
• The five-year high for Share-based Compensation was $36.1 million in Q1 2025, with the low at $5.6 million in Q1 2022.
• Historically, Share-based Compensation has averaged $17.4 million across 5 years, with a median of $16.5 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation soared 209.28% — and 2026, when it slumped 38.39%.
• Recursion Pharmaceuticals' Share-based Compensation stood at $7.7 million in 2022, then jumped by 109.04% to $16.1 million in 2023, then surged by 91.37% to $30.8 million in 2024, then retreated by 22.81% to $23.8 million in 2025, then slipped by 6.51% to $22.2 million in 2026.
• The last three Share-based Compensation figures came in at $22.2 million (Q1 2026), $23.8 million (Q4 2025), and $25.2 million (Q3 2025), per Business Quant data.